News

Op2Lysis is in Ouest-France

As a follow-up of our settlement with a new company settlement in Caen, Op2Lysis communicates in Ouest-France.

The article is available at the following address
https://www.ouest-france.fr/normandie/caen-14000/caen-une-start-travaille-sur-l-accident-vasculaire-cerebral-5363174

NETVA 2017 – A week of immersion / networking in Boston

One week of immersion in Boston, thanks to the NETVA program, coordinated by the Consulat de France in Boston, allowed us to benefit from the consulate network, as they introduced us into the biggested US ecosystem for Biotechs, including VCs, the local teams of Business France and of the French Tech Hub, preclinical CROs, and lawyers. We also met with renowned neurologists, emergency room physicians and neurosurgeons, as well as with neuroimaging specialists from Boston’s main hospitals (MGH, BU Hospital, Beth Israel). These early academic feedbacks were very encouraging on the potential of the therapeutic option that we develop.

More information about stroke and first care is needed

This is the conclusion of a survey led by the French stroke foundation on 986 people in October 2017. The questionnaire, which is available on the web, shows that one out of three people do not dial the emergency telephone number when facingstroke symptoms.

As a reminder, STROKE requires FAST action

(http://www.stroke.org/understand-stroke/recognizing-stroke/act-fast)

Sunday, 29 October – World Stroke Day

Question : Do you know about your blood pressure ?

90 % of the stroke events are related to ten modifiable risk factors. Prof. Serge Timsit, Neurologist and President of the « Société Française Neuro-Vasculaire (SFNV) » reports below.

http://www.francetvinfo.fr/sante/drogue-addictions/lutte-contre-le-tabagisme/avc-90-des-accidents-vasculaires-cerebraux-dependent-de-dix-facteurs-de-risque-modifiables_2441293.html

Op2Lysis US patent granted

The patent covering Op2Lysis’ O2L-001 innovation for the treatment of patients with a hemorrhagic stroke has been granted in the United States of America by the USPTO in July 2017.

A specific press release is available below

–> Click here  <–

R&D site opening in Caen

We are proud to announce the grand opening of our R&D site in Caen, at the Cyceron Center, where the Op2Lysis technology was invented. We also took the opportunity to show the laboratory to Estelle Louet, our first employee, who should join the team by December 2017 to work with us while pursuing her doctoral studies for a PhD level.

kick off of the Op2Lysis Crowdfunding campaign on WiSEED – Fundraising #1

As a result of a long and hard work, which was led over these last months and allowed a revision of the terms negotiated for the O2L-001 license, as well as gaining non-dilutive fundings (i-LAB and loans on trust) and numerous prizes and recognitions, Op2Lysis initiated its crowdfunding campaign on the WiSEED.com platform.

The objective of this fundraising is to fund the feasibility of the industrial production and formulation of O2L-001 over the next 12 months. At the end of this first period of our development program, we will have sufficient information on production, purification, and formulation to initiate the regulatory preclinical steps of O2L-001 development, with a compound able to liquefy an intracerebral hematoma with one single injection. Scale-up and preparation of the regulatory studies will require a second fundraising for 2019.

French–Flemish meetings with the FIT Agency

September 2017 – French-Flemish meeting with the FIT Agency in Leuven (BE)

Op2Lysis was in Leuven during the French-Flemish meetings, which were organized by Flanders Investment and Trade (FIT). Great meeting opportunities.

 

 

 

Prof. Denis Vivien was in Berlin for the 26th ISTH session

Prof. Denis Vivien was invited to attend ISTH (International Society on Thrombosis and Haemostasis) in Berlin (Germany) and present his lab’s experience on preclinical models of ischemic or hemorrhagic strokes. He also introduced STROKE@LLIANCE, a program that was launched to improve the translational progress of drug candidates towards clinical stage through mimicking at the preclinical lab stage the heterogeneity of early clinical phases.

http://isthcongressdaily.org/neurobiology-stroke-stroke-models-time-compromise/ 

Op2Lysis is a NETVA Laureate

Op2Lysis was selected as a Laureate among 20 for NETVA 2017. This will allow us to go to BOSTON during the second part of the year to better understand the North American market (including regulations and hospital needs), as well as the biotechnology ecosystem to identify potential partners and investors.

The NETVA Press Release.

About NETVA

The New Technology Venture Accelerator (NETVA) is a program of preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC.

Each year, 15 French startups are selected though a national competition after evaluation by juries in France and the program’s three American cities. In 2015, the program was expanded to Canada.

The selected laureates begin their preparation for US markets with a two-day training seminar in France. Each laureate is also paired with one or more American mentors prior to an intense week of immersion in the United States. The laureates then have the opportunity to network with high-level American academic and technological partners and to benefit from an additional series of training workshops focused on how to approach and succeed in American markets.

For more information : www.netvafrance.com – contact [at] netvafrance.com